Amerigen Pharmaceuticals’ Chinese subsidiary, Suzhou Amerigen Pharmaceuticals Co., Ltd., has entered into a marketing and distribution agreement with Sinochem Jiangsu Pharmaceutical Co., Ltd. for Amerigen's generic mecobalamin 0.5mg immediate release tablets. Amerigen will manufacture the product at its U.S. FDA approved and China CFDA certified finished solid dose facility in Suzhou.
Sinochem has exclusive sales and distribution rights to the product in China in exchange for undisclosed payments to Amerigen. The first commercial shipments of the product, which will be sold under Suzhou Amerigen's label, are expected in mid-2014. The companies will seek regulatory approvals required for the commercialization of the product in China under the new collaboration.
John Lowry, Amerigen's president and chief executive officer, said, "This agreement is a continuation of our strategy to bring high quality and locally manufactured generic products to the rapidly growing Chinese market by leveraging Amerigen's FDA and CFDA licensed manufacturing facility in Suzhou. Our collaboration with Sinochem enables expedited market entry through the sales expertise of a highly reputable and leading Chinese pharmaceutical company."
Mr. Ziqiang Wu, general manager of Sinochem Pharma, said, "Sinochem Pharma is pleased to cooperate with Amerigen, a renowned pharmaceutical company in China which has passed on-site inspections by the U.S. FDA and China CFDA. We will commit to work together, realize complementary advantages and promote drug products of high quality manufactured by Amerigen in the Chinese market through our joint efforts. The mecobalamin tablet project is just the beginning of the cooperation between our two companies, and we will discuss further business collaborations in the future."
Suzhou Amerigen, Sinochem in Marketing, Distribution Pact
Published September 26, 2013
blog comments powered by Disqus